SciELO - Scientific Electronic Library Online

 
vol.34 número4Carcinoma pseudohiperplásico con cambios xantomatosos: una neoplasia que semeja hiperplasia glandular de la próstataEvaluación del test PCA3 para el diagnóstico de cáncer de próstata: revisión sistemática y metanálisis índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google

Compartir


Actas Urológicas Españolas

versión impresa ISSN 0210-4806

Resumen

FLORIANO-SANCHEZ, E.; CASTRO-MARIN, M.; CARDENAS-RODRIGUEZ, N.  y  LARA-PADILLA, E.. Evaluation of the expression of p22 phox subunit of NADPH oxidase (NOX) in prostate cancer and benign prostatic hyperplasia: A comparative study. Actas Urol Esp [online]. 2010, vol.34, n.4, pp.340-345. ISSN 0210-4806.

Introduction and objective: Recent reports found that prostate cancer is the second most common cancer and second leading cause of cancer death in men. Methods and results: 62 samples were obtained (30 of patients with cancer and 32 of patients with hyperplasia) collected from January 2004 to december 2007. Was conducted a clinical, experimental, transversal, comparative and descriptive trial. Were followed the inclusion (cancer or hyperplasia diagnosis), exclusion (patients not authorized to participate in the study or not candidates for resection of prostate) and elimination (damage tissue) criteria. Was detected by immunohistochemistry the presence of p22 phox NADPH oxidase subunit in patients with prostate cancer and prostatic hyperplasia from the formation of avidin-biotin complex using diaminobenzidine as a dye contrast. The statistical analysis was determined with t test (Graph Prism 3.0 software) considering p<0.05 for statistical differences. The results of the immunoreactivity of p22 phox in the stroma and gland of the prostate showed an increase in prostate cancer (8.45±3.6 and 25.08±7.5% p<0.0001, respectively) in comparison with the results for prostatic hyperplasia (4.8±2.8 and 6.7±3.1% p<0.0001, respectively). Conclusions: The over-expression of the NADPH oxidase is involved in the prostate cancer. Moreover, we suggested that the NADPH oxidase, in combination with other classical markers, could be an indicator for the post-treatment monitoring of the patients diagnosed with hyperplasia and others minors pathologies of the prostate.

Palabras clave : Prostate cancer; Benign prostatic hyperplasia; Reactive oxygen species; p22 phox; NADPH oxidase.

        · resumen en Español     · texto en Español     · Español ( pdf )

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons